Location of Repository

Evaluation of the Adenocarcinoma-Associated Gene AGR2 and the Intestinal Stem Cell Marker LGR5 as Biomarkers in Colorectal Cancer

By Manuel Valladares-Ayerbes, Moisés Blanco-Calvo, Margarita Reboredo, María J. Lorenzo-Patiño, Pilar Iglesias-Díaz, Mar Haz, Silvia Díaz-Prado, Vanessa Medina, Isabel Santamarina, Sonia Pértega, Angélica Figueroa and Luis M. Antón-Aparicio

Abstract

We aim to estimate the diagnostic performances of anterior gradient homolog-2 (AGR2) and Leucine-rich repeat-containing-G-protein-coupled receptor 5 (LGR5) in peripheral blood (PB) as mRNA biomarkers in colorectal cancer (CRC) and to explore their prognostic significance. Real-time PCR was used to analyze AGR2 and LGR5 in 54 stages I-IV CRC patients and 19 controls. Both mRNAs were significantly increased in PB from CRC patients compared to controls. The area under the receiver-operating characteristic curves were 0.722 (p = 0.006), 0.376 (p = 0.123) and 0.767 (p = 0.001) for AGR2, LGR5 and combined AGR2/LGR5, respectively. The AGR2/LGR5 assay resulted in 67.4% sensitivity and 94.7% specificity. AGR2 correlated with pT3–pT4 and high-grade tumors. LGR5 correlated with metastasis, R2 resections and high-grade. The progression-free survival (PFS) of patients with high AGR2 was reduced (p = 0.037; HR, 2.32), also in the stage I-III subgroup (p = 0.046). LGR5 indicated a poor prognosis regarding both PFS (p = 0.007; HR, 1.013) and overall survival (p = 0.045; HR, 1.01). High AGR2/LGR5 was associated with poor PFS (p = 0.014; HR, 2.8) by multivariate analysis. Our findings indicate that the assessment of AGR2 and LGR5 in PB might reflect the presence of circulating tumor cells (CTC) and stem cell like CTC in CRC. Increased AGR2 and LGR5 are associated with poor outcomes

Topics: Article
Publisher: Molecular Diversity Preservation International (MDPI)
OAI identifier: oai:pubmedcentral.nih.gov:3344219
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2 −ΔΔCt method. Methods
    2. (2008). Antó n-Aparicio, L.M. Bioinformatics approach to mRNA markers discovery for detection of circulating tumor cells in patients with gastrointestinal cancer. Cancer Detect.
    3. (2007). Blood markers for early detection of colorectal cancer, a systematic review. Cancer Epidemiol.
    4. (2008). Cancer stem cells in solid tumors, accumulating evidence and unresolved questions.
    5. (2010). Circulating tumor cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted
    6. Circulating tumor cells, not all detected cells are bad and not all bad cells are detected.
    7. (2002). Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer, results of a multivariate analysis of 3825 patients.
    8. (2011). Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with
    9. (1988). Comparing the areas under two or more correlated receiver operating curves, a nonparametric approach. Biometrics
    10. Cytokeratin 20 is not a tissue-specific marker for the detection of malignant epithelial cells in the blood of colorectal cancer patients.
    11. (1998). Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin. Cancer Res.
    12. (2011). European cancer mortality predictions for the year 2011.
    13. Evaluation of plakophilin-3 mRNA as a biomarker for detection of circulating tumor cells in gastrointestinal cancer patients.
    14. (2005). Global gene expression profiling of circulating tumor cells. Cancer Res.
    15. (1998). hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines.
    16. (2005). Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res.
    17. (2006). Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors. Cancer Biol. Ther.
    18. (2007). Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature
    19. (2007). Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients. Prostate Cancer Prostatic Dis.
    20. (2010). Increased plasma concentrations of anterior gradient 2 protein are positively associated with ovarian cancer.
    21. (2010). Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology
    22. (2011). Methylation of cancer-stem-cell-associated WNT target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell
    23. (2006). Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res.
    24. (2011). mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin. Cancer Res.
    25. (2010). Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients. World
    26. (2010). Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 in colorectal cancer. Cancer Sci.
    27. (2001). Phases of biomarker development for early detection of cancer.
    28. (2010). Prognostic significance of circulating tumor cells following surgical resection of colorectal cancers, a systematic review.
    29. Prognostic value of putative circulating cancer stem cells in patients undergoing hepatic resection for colorectal liver metastasis.
    30. (2008). Quantitative RT-PCR detection of colorectal tumor cells in peripheral blood—A systematic review.
    31. (2006). Real-time reverse transcription PCR and the detection of occult disease in colorectal cancer.
    32. (2008). Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal
    33. (2005). Statistics subcommittee of the NCI-EORTC working group on cancer diagnostics.
    34. (2009). Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res.
    35. (2008). The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res.
    36. The clinical significance of circulating tumor cells in non-metastatic colorectal cancer. A review.
    37. (2011). The human adenocarcinoma-associated gene, AGR2, induces expression of amphiregulin through HIPPO pathway co-activator YAP1 activation.
    38. (2011). The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell
    39. (2009). The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients.
    40. (2012). The MIQE guidelines, minimum information for publication of quantitative real-time PCR experiments.
    41. (2012). The protein disulfide isomerase AGR2 is essential for production of intestinal mucus.
    42. (2008). Validation of biomarker based risk prediction models. Clin. Cancer Res.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.